Full-Time

Biostatistical Programming Manager

Posted on 6/22/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$129.1k - $174.6k/yr

+ Annual bonus + Stock-based long-term incentives

Remote in USA

Remote

Bachelor's, Master's, PhD, Associate's

Category
Biology & Biotech (1)
Required Skills
Python
SAS
Data Visualization
R
SQL

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A doctorate degree, or a master’s degree and 2 years of statistical programming experience, or a bachelor’s degree and 4 years of statistical programming experience, or an associate’s degree and 8 years of statistical programming experience, or a high school diploma/GED and 10 years of statistical programming experience.
  • 6+ years of statistical programming experience in the biopharmaceutical industry.
  • Experience with regulatory submissions.
  • Strong hands-on SAS programming expertise, including SAS Base, SAS Macro, SQL, SAS/Graph, and SAS Stat packages.
  • Experience with R programming for clinical trial analyses, data manipulation, reporting, and visualization.
  • Familiarity with additional programming languages and tools such as Python.
  • Hands-on experience developing and validating SDTM and ADaM datasets and Tables, Listings, and Figures.
  • A thorough understanding of clinical trial processes from data collection through analysis and reporting.
  • Ability to lead programmers in completing study programming activities and provide guidance on technical and process questions.
  • Strong understanding of data standards and compliance checks, including Pinnacle 21.
  • Experience providing quality oversight for outsourced and internal programming deliverables.
  • Ability to troubleshoot complex technical issues and turn around at-risk projects.
  • Experience working in a globally dispersed team on Phase 1–4 clinical trials.
  • Strong oral and written English communication skills, collaboration, negotiation, and organizational skills.
Responsibilities
  • Provide rapid-response statistical programming support for urgent internal and external requests.
  • Serve as a lead programmer for studies and projects, including Data Access Plan activities, unblinding efforts, and special projects.
  • Deliver hands-on programming support for SDTM, ADaM, Tables, Listings, and Figures, and other study and regulatory submission deliverables as needed.
  • Oversee the execution and quality of projects managed by FSP partners according to the Amgen Global Statistical Programming Quality Oversight Plan.
  • Ensure that FSP and in-house programming deliverables meet quality, compliance, timeline, and productivity expectations.
  • Mitigate at-risk projects by providing technical expertise, programming support, and operational guidance.
  • Contribute to developing and delivering training materials for internal teams and FSP partners.
  • Provide guidance and technical consultation to study programming teams on Amgen processes, tools, and utilities.
  • Lead or contribute to Global Statistical Programming continuous-improvement initiatives and cross-functional activities, including inspection readiness, process improvement, innovation, and training.
  • Contribute to programming-team performance-metrics development, data collection, and reporting.
  • Review project documentation, including specifications, issue logs, and deliverable status, for accuracy and completeness.
Desired Qualifications
  • A master’s degree in Statistics, Mathematics, Computer Science, Life Sciences, or another relevant scientific subject.
  • Experience supporting clinical development programs within the Obesity Therapeutic Area.
  • Understanding of obesity clinical endpoints, data standards, and regulatory considerations.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion; guidance increased to $38.2-$39.4 billion.
  • Repatha grew 37%, Evenity 38%, and Uplizna 90% in Q2 2026.
  • Colorado’s Enbrel price cap was blocked on July 1, 2026, preserving legacy cash flow.

What critics are saying

  • FDA proposed Tavneos withdrawal on April 27, 2026; a hearing loss kills ChemoCentryx economics.
  • Tavneos retraction and liver-injury findings threaten Amgen’s credibility with regulators and investigators in 2026.
  • Prolia erosion and patent battles, including Delaware’s June 2026 verdict, pressure margins until 2027.

What makes Amgen unique

  • MariTide’s monthly-to-quarterly dosing targets obesity convenience versus weekly GLP-1 rivals in 2027.
  • Amgen’s 2026 base is unusually diversified: Repatha, Evenity, Uplizna, Tezspire, and Imdelltra.
  • Amgen’s 2027 Hyderabad Science and Innovation Center expands AI-linked discovery capacity globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.

PR Newswire
Aug 4th, 2026
Amgen reports 10% revenue growth to $10.1B in Q2 2026, driven by 26% surge in six key growth products

Amgen reported second quarter 2026 revenues of $10.1 billion, a 10% increase year-over-year. Product sales grew 9%, driven by volume growth across 22 products that achieved double-digit sales growth. The company's six key growth drivers grew 26% year-over-year, generating nearly 70% of second quarter product sales. GAAP earnings per share increased 65% to $4.37, whilst non-GAAP EPS rose 4% to $6.29. Notable product performance included Repatha sales increasing 37% to $953 million and EVENITY growing 38% to $714 million. The company generated $3.5 billion in free cash flow, compared to $1.9 billion in the prior year period. For full year 2026, Amgen expects total revenues between $38.2 billion and $39.4 billion, with non-GAAP EPS guidance of $22.30 to $23.50.

INACTIVE